Introducing Cris Constantinescu
We are pleased to introduce Cris Constantinescu as the new Editor in Chief for the European Neurological Review. In this interview Prof. Constantinescu discusses his research interests and his aims for the journal over the next year.
INTRODUCING THE NEW EUROPEAN NEUROLOGICAL REVIEW EDITOR-IN-CHIEF, CRIS CONSTANTINESCU
FILMED AT THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) ANNUAL MEETING, SEPTEMBER 2016
COULD YOU TELL US A LITTLE ABOUT YOURSELF AND YOUR CAREER TO DATE?
00:16 – So I’ve been in Nottingham, working as a neurologist for the last 17 years. Previously, I studied medicine at Boston University in the United States, and I did some training in neurology, in Philadelphia, at the University of Pennsylvania. That was my neurology residency, and then I did some fellowships in neuroimmunology and neurorehabilitation, also at Penn, and I ended up doing a PhD in immunology at Penn. After that, I worked for a while in the United States, and then I moved to Europe. I worked in Switzerland in the MS team for about two years. And then, as I said, about 17 years ago, I moved to Nottingham. In 2004, I became Professor and Head of the… Chair of the division of Clinical Neurology at Nottingham.
WHAT ARE YOUR MAIN RESEARCH INTERESTS?
01:30 – So my main research interest is in multiple sclerosis. I’ve been very interested in immunological aspects of MS; MS is an autoimmune disease. And I was looking at immunological mechanisms, in particular cytokine dysregulation in MS, so the balance between pro- and anti-inflammatory cytokines which seems to be dysregulated in MS; and also modalities of modulating the immune system to treat MS.
02:05 – And since the early days, that was a main aim of our research and now, of course, most of the drugs that we have for MS now are doing this; are aiming at modulating the immune system in a way in which the inflammation is reduced in the brain. So I think, in that respect, I worked from the preclinical models to phase 4 clinical trials in MS.
02:38 – And also, another interest of mine has been imaging in MS, so I have done some, and still do some work in terms of finding modalities to image the white matter and grey matter damage caused by the MS. And, in particular, as it relates to discovering subtle disease, on the one hand, and on the other hand, perhaps finding ways to use these imaging modalities as outcome measures in clinical trials, or for following the natural history of MS.
WHAT DO YOU CONSIDER THE GREATEST STRENGTHS OF EUROPEAN NEUROLOGICAL REVIEW AND WHAT ARE YOUR AIMS FOR THE JOURNAL OVER THE NEXT YEAR?
03:23 – In each issue, it has topics that cover neurology in general. I think it’s a unique source almost for writing about meetings, and what’s been discussed at meetings or satellite symposia of specific meetings, and I think that’s one of the strengths of the journal. The quality of the reviews is always very high, I think; that would be an important thing. Maybe diversifying the topics, perhaps finding some new topics. Not just therapeutics, but maybe some topics about diagnostic methods, some topics about various clinical aspects, or maybe new research in various neurological diseases. I think that would be great. And I hope that by doing that, the quality of the journal will increase and also perhaps the journal would be able to be included in PubMed, which would be a great advantage and a great incentive for people to submit papers to the journal.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!